Clinical and biochemical characteristics of nonobese type 2 diabetic patients with glutamic acid decarboxylase antibody in Korea

Chul Sik Kim, Jae Hyun Nam, Ji Sun Nam, Jong Suk Park, Eun Seok Kang, Chul Woo Ahn, Bong Soo Cha, Sungkil Lim, Kyung Rae Kim, Hyun Chul Lee, Kap Bum Huh

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

We evaluated the prevalence of glutamic acid decarboxylase autoantibody (GADA) in nonobese patients with type 2 diabetes mellitus in Korea and investigated the characteristics of GADA-positive and GADA-negative patients. Two years later, we assessed the progression of beta-cell function in these patients. Of the 647 nonobese patients with type 2 diabetes mellitus enrolled in the study, 10.1% was positive for GADA. Glutamic acid decarboxylase antibody-positive patients had lower fasting and stimulated C-peptide levels compared with GADA-negative patients (1.70 ± 0.72 vs 1.24 ± 0.59 μg/L, P < .001; 2.59 ± 1.51 vs 1.99 ± 0.82 μg/L, P < .001). Patients treated with insulin had lower fasting and stimulated C-peptide levels than those not treated (1.13 ± 0.52 vs 1.66 ± 0.73 μg/L, P = .002; 1.85 ± 0.69 vs 2.49 ± 0.91 μg/L, P = .004) and had higher titers of GADA (30.5 ± 7.3 vs 6.0 ± 4.8 U/mL, P < .001). In terms of progression of beta-cell function, fasting and stimulated C-peptide levels were significantly lower in GADA-positive patients after 2 years (from 1.24 ± 0.59 to 0.95 ± 0.54 μg/L, P = .004; from 1.99 ± 0.82 to 1.61 ± 0.77 μg/L, P = .007), whereas no such difference was observed in the GADA-negative patients. We demonstrate that a significant proportion of Korean patients may be positive for GADA; this is consistent with studies of white subjects, although disagrees with previous reports on Korean subjects. By assessing the presence of GADA in Korean type 2 diabetic patients, we are able to predict their course of beta-cell function and identify in advance those who are likely to require insulin treatment.

Original languageEnglish
Pages (from-to)1107-1112
Number of pages6
JournalMetabolism: Clinical and Experimental
Volume55
Issue number8
DOIs
Publication statusPublished - 2006 Aug 1

Fingerprint

Glutamate Decarboxylase
Korea
Autoantibodies
Antibodies
C-Peptide
Fasting
Type 2 Diabetes Mellitus
Insulin

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Kim, Chul Sik ; Nam, Jae Hyun ; Nam, Ji Sun ; Park, Jong Suk ; Kang, Eun Seok ; Ahn, Chul Woo ; Cha, Bong Soo ; Lim, Sungkil ; Kim, Kyung Rae ; Lee, Hyun Chul ; Huh, Kap Bum. / Clinical and biochemical characteristics of nonobese type 2 diabetic patients with glutamic acid decarboxylase antibody in Korea. In: Metabolism: Clinical and Experimental. 2006 ; Vol. 55, No. 8. pp. 1107-1112.
@article{1b22191e2d16414484464e292edcf10a,
title = "Clinical and biochemical characteristics of nonobese type 2 diabetic patients with glutamic acid decarboxylase antibody in Korea",
abstract = "We evaluated the prevalence of glutamic acid decarboxylase autoantibody (GADA) in nonobese patients with type 2 diabetes mellitus in Korea and investigated the characteristics of GADA-positive and GADA-negative patients. Two years later, we assessed the progression of beta-cell function in these patients. Of the 647 nonobese patients with type 2 diabetes mellitus enrolled in the study, 10.1{\%} was positive for GADA. Glutamic acid decarboxylase antibody-positive patients had lower fasting and stimulated C-peptide levels compared with GADA-negative patients (1.70 ± 0.72 vs 1.24 ± 0.59 μg/L, P < .001; 2.59 ± 1.51 vs 1.99 ± 0.82 μg/L, P < .001). Patients treated with insulin had lower fasting and stimulated C-peptide levels than those not treated (1.13 ± 0.52 vs 1.66 ± 0.73 μg/L, P = .002; 1.85 ± 0.69 vs 2.49 ± 0.91 μg/L, P = .004) and had higher titers of GADA (30.5 ± 7.3 vs 6.0 ± 4.8 U/mL, P < .001). In terms of progression of beta-cell function, fasting and stimulated C-peptide levels were significantly lower in GADA-positive patients after 2 years (from 1.24 ± 0.59 to 0.95 ± 0.54 μg/L, P = .004; from 1.99 ± 0.82 to 1.61 ± 0.77 μg/L, P = .007), whereas no such difference was observed in the GADA-negative patients. We demonstrate that a significant proportion of Korean patients may be positive for GADA; this is consistent with studies of white subjects, although disagrees with previous reports on Korean subjects. By assessing the presence of GADA in Korean type 2 diabetic patients, we are able to predict their course of beta-cell function and identify in advance those who are likely to require insulin treatment.",
author = "Kim, {Chul Sik} and Nam, {Jae Hyun} and Nam, {Ji Sun} and Park, {Jong Suk} and Kang, {Eun Seok} and Ahn, {Chul Woo} and Cha, {Bong Soo} and Sungkil Lim and Kim, {Kyung Rae} and Lee, {Hyun Chul} and Huh, {Kap Bum}",
year = "2006",
month = "8",
day = "1",
doi = "10.1016/j.metabol.2006.04.006",
language = "English",
volume = "55",
pages = "1107--1112",
journal = "Metabolism: Clinical and Experimental",
issn = "0026-0495",
publisher = "W.B. Saunders Ltd",
number = "8",

}

Clinical and biochemical characteristics of nonobese type 2 diabetic patients with glutamic acid decarboxylase antibody in Korea. / Kim, Chul Sik; Nam, Jae Hyun; Nam, Ji Sun; Park, Jong Suk; Kang, Eun Seok; Ahn, Chul Woo; Cha, Bong Soo; Lim, Sungkil; Kim, Kyung Rae; Lee, Hyun Chul; Huh, Kap Bum.

In: Metabolism: Clinical and Experimental, Vol. 55, No. 8, 01.08.2006, p. 1107-1112.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Clinical and biochemical characteristics of nonobese type 2 diabetic patients with glutamic acid decarboxylase antibody in Korea

AU - Kim, Chul Sik

AU - Nam, Jae Hyun

AU - Nam, Ji Sun

AU - Park, Jong Suk

AU - Kang, Eun Seok

AU - Ahn, Chul Woo

AU - Cha, Bong Soo

AU - Lim, Sungkil

AU - Kim, Kyung Rae

AU - Lee, Hyun Chul

AU - Huh, Kap Bum

PY - 2006/8/1

Y1 - 2006/8/1

N2 - We evaluated the prevalence of glutamic acid decarboxylase autoantibody (GADA) in nonobese patients with type 2 diabetes mellitus in Korea and investigated the characteristics of GADA-positive and GADA-negative patients. Two years later, we assessed the progression of beta-cell function in these patients. Of the 647 nonobese patients with type 2 diabetes mellitus enrolled in the study, 10.1% was positive for GADA. Glutamic acid decarboxylase antibody-positive patients had lower fasting and stimulated C-peptide levels compared with GADA-negative patients (1.70 ± 0.72 vs 1.24 ± 0.59 μg/L, P < .001; 2.59 ± 1.51 vs 1.99 ± 0.82 μg/L, P < .001). Patients treated with insulin had lower fasting and stimulated C-peptide levels than those not treated (1.13 ± 0.52 vs 1.66 ± 0.73 μg/L, P = .002; 1.85 ± 0.69 vs 2.49 ± 0.91 μg/L, P = .004) and had higher titers of GADA (30.5 ± 7.3 vs 6.0 ± 4.8 U/mL, P < .001). In terms of progression of beta-cell function, fasting and stimulated C-peptide levels were significantly lower in GADA-positive patients after 2 years (from 1.24 ± 0.59 to 0.95 ± 0.54 μg/L, P = .004; from 1.99 ± 0.82 to 1.61 ± 0.77 μg/L, P = .007), whereas no such difference was observed in the GADA-negative patients. We demonstrate that a significant proportion of Korean patients may be positive for GADA; this is consistent with studies of white subjects, although disagrees with previous reports on Korean subjects. By assessing the presence of GADA in Korean type 2 diabetic patients, we are able to predict their course of beta-cell function and identify in advance those who are likely to require insulin treatment.

AB - We evaluated the prevalence of glutamic acid decarboxylase autoantibody (GADA) in nonobese patients with type 2 diabetes mellitus in Korea and investigated the characteristics of GADA-positive and GADA-negative patients. Two years later, we assessed the progression of beta-cell function in these patients. Of the 647 nonobese patients with type 2 diabetes mellitus enrolled in the study, 10.1% was positive for GADA. Glutamic acid decarboxylase antibody-positive patients had lower fasting and stimulated C-peptide levels compared with GADA-negative patients (1.70 ± 0.72 vs 1.24 ± 0.59 μg/L, P < .001; 2.59 ± 1.51 vs 1.99 ± 0.82 μg/L, P < .001). Patients treated with insulin had lower fasting and stimulated C-peptide levels than those not treated (1.13 ± 0.52 vs 1.66 ± 0.73 μg/L, P = .002; 1.85 ± 0.69 vs 2.49 ± 0.91 μg/L, P = .004) and had higher titers of GADA (30.5 ± 7.3 vs 6.0 ± 4.8 U/mL, P < .001). In terms of progression of beta-cell function, fasting and stimulated C-peptide levels were significantly lower in GADA-positive patients after 2 years (from 1.24 ± 0.59 to 0.95 ± 0.54 μg/L, P = .004; from 1.99 ± 0.82 to 1.61 ± 0.77 μg/L, P = .007), whereas no such difference was observed in the GADA-negative patients. We demonstrate that a significant proportion of Korean patients may be positive for GADA; this is consistent with studies of white subjects, although disagrees with previous reports on Korean subjects. By assessing the presence of GADA in Korean type 2 diabetic patients, we are able to predict their course of beta-cell function and identify in advance those who are likely to require insulin treatment.

UR - http://www.scopus.com/inward/record.url?scp=33745826667&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745826667&partnerID=8YFLogxK

U2 - 10.1016/j.metabol.2006.04.006

DO - 10.1016/j.metabol.2006.04.006

M3 - Article

VL - 55

SP - 1107

EP - 1112

JO - Metabolism: Clinical and Experimental

JF - Metabolism: Clinical and Experimental

SN - 0026-0495

IS - 8

ER -